Pfizer asks docs to sign ‘Dear Insurer’ letters

Share this article:
Pfizer is enlisting doctors in its efforts to stave off generic erosion of Lipitor. The company has supplied doctors with a CD containing letters they can send to pharmacists and insurers petitioning them not to switch patients from Lipitor to a generic statin, according to USA Today. Public Citizen’s Sidney Wolf told the paper that the company was using doctors as “human shields” to protect its business. “I would say it’s unethical,” said Wolf. Merck’s Zocor (simvastatin) went off-patent last June. Lipitor, which loses exclusivity in 2010, is also struggling to preserve its market share against branded competitors Vytorin, from Merck/Schering-Plough, and Crestor, from AstraZeneca. Pfizer scored a Lipitor patent victory yesterday when The Supreme Court declined to intervene in Ranbaxy Laboratories appeal of a lower-court ruling upholding a Pfizer patent for Lipitor. Indian generics firm Ranbaxy was seeking to sell a generic version of Lipitor. The court's decision not to get involved appears to settle the matter in Pfizer's favor.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...